Don’t Route Around the Liver. Distract It.
Nanobiotix presented AACR data for Nanoprimer, a decoy nanoparticle that saturates liver clearance before LNP dosing.
Jeff Martin
Immunofoco Already Has a Phase 3 CAR-T. Now It’s Making Them Inside the Patient.
Immunofoco presented preclinical data for IMV102, an in vivo BCMA CAR-T built on its iMAGIC lentiviral platform.
EpiBiologics Is Taking Extracellular Protein Degradation Into The Clinic
EpiBiologics dosed the first patient with EPI-326, a bispecific antibody degrader hitting wild-type and mutant EGFR.
Whitehawk Already Has Two ADCs in the Clinic. A Third Is on Deck.
Whitehawk Therapeutics plans a mid-2026 IND for HWK-206, a biparatopic SEZ6-targeting ADC.
Evaxion Picked The Target in 2023. The Immune Response Is Still Holding.
Evaxion reports 86% target precision and two-year durable immune responses for its AI-designed EVX-01 melanoma vaccine.
Akamis Bio Hits 50% Response in pMMR Rectal Cancer
Akamis Bio reports 50% response rate with NG-350A oncolytic virus plus chemoradiation in pMMR rectal cancer.
Drug Farm Reversed Anhidrosis in Four of Six ROSAH Patients
Drug Farm reports Phase 1b data for DF-003, reversing anhidrosis in patients with the ultra-rare ROSAH syndrome.
Nested Hits 38% in Class II/III Melanoma With No Options Left
Nested Therapeutics posts first Phase 1 data for NST-628, showing clinical activity in NRAS and BRAF Class II/III melanoma.
Soley Drugged CKAP2. Everyone Said It Was Undruggable.
Soley Therapeutics unveils STX-6398, a first-in-class CKAP2 modulator targeting a protein previously considered undruggable.
OncoNano Delivers MMAE to Tumors Without an Antibody
OncoNano Medicine presents preclinical data for ONM-421, an antigen-free polymer-drug conjugate delivering MMAE to solid tumors.